Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACH adjuvant trastuzumab plus chemotherapy safety study in HER2-positive breast cancer
2006-005780-26Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin, cyclophosphamide, trastuzumab, doxorubicin and paclitaxel in breast cancer (2 arms), sponsored by Merck & Co. Primary endpoint: Overall incidence of cardiac events or inability to administer trastuzumab. Started Apr 2007; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-005780-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005780-26.